Global Peptide Cancer Drug Market, Dosage, Price, Sales & Clinical Trials Insight 2029

Abstract
Global Peptide Cancer Drug Market, Dosage, Price, Sales & Clinical Trials Insight 2029 Report Highlights:

• Global Peptide Drug Market Opportunity: > USD 15 Billion
• Marketed Cancer Peptides Drugs Sales Insight 2019 – 2023
• Marketed Cancer Peptides Drugs Dosage, Patent& Price Insight
• Marketed Cancer Peptides Drugs Clinical & Commercial Insight: 25 Drugs
• Peptide Cancer Drug Clinical Trials Insight: > 200 Drugs
• Global Peptide Cancer Drug Clinical Trials Insight By Company, Country Indication & Phase
• Peptide Drug Development Proprietary Technologies By Company & Indication

Biologics have been an important class of drugs for several diseases including cancer. Till now, antibodies have dominated this domain of therapeutics but driven by new technological innovations, researchers have now shifted their new drug development approach towards peptides as preferred choice of anti-cancer agents. For a long time, peptides have been used as therapeutic agents; however, their potential in cancer has been a new area of interest. Due to their ability to offer advanced optimization strategies, peptide drugs have become an attractive area of research.

The development of peptide based drugs and therapies have made great progress in the last decade owing to several pharmaceutical companies developing novel proprietary technologies for producing innovative peptide therapeutics. For instance, South Korea’s Nanotechnology and Integrated Bioengineering Centre (NBICE), pharmaceutical company has developed its own novel peptide therapeutic discovery and delivery technology platform called TOPscovery. The company has also created a subsequent clinical pipeline using this novel technology platform which is based on target oriented peptide therapeutic discovery and has target tissue / cell penetrating peptide delivery platform to delivery protein or antibody or siRNA into the target tissue such as that of the cancer cells.

This peptide discovery platform TOPscovery is focused on resolving fibrosis in liver, lung and heart and additionally, the platform technology to target tissue penetrating peptide carrier (NPEP – TPP) can be applied to protein, antibody having intracellular targets, this increase the efficacy and decreases the side effects to non – target. The development of proprietary platforms and novel technologies has been an increasingly important factor that is boosting innovation the today’s development of peptide based anti-cancer therapies.

Moreover, the increasing number of companies collaborating and investing in the field is also a signification factor driving the growth of peptide therapeutics. A major reason of this has been the development of novel technologies. With more pharmaceutical companies and biotechs advancing their portfolio with innovative products developed from novel platforms, more companies gain interest in field which could ultimately lead to more collaboration or investment, increasing the overall competitive landscape of the merging global market of anti – cancer peptide therapies.

The trend of collaboration not only extends the research and development capabilities for both the companies but it also allows for assessing the investigational peptide product candidates and likely have an impact on global peptide therapeutic market in terms of increasing the pipeline of cancer peptides, advancements in discovery and optimization of products and the possibility of investigational several different combinational strategies.

For instance, in first quarter of 2023, PeptiDream announced a collaborative arrangement with Ono Pharmaceuticals to discover and develop novel macrocyclic constrained peptide-based drugs directed against targets chosen by Ono. Under the agreement, PeptiDream will apply its proprietary PDPS (Peptide Discovery Platform System) technology to identify and enhance macrocyclic constrained peptide drug candidates, while Ono will develop and commercialize the resulting peptide-based drugs globally under an exclusive license. PeptiDream will be eligible to receive an undisclosed upfront payment in addition to funding to carry out research, as well as added payments based on research, development and commercialization milestones based on global net sales.

In addition, the portfolio of novel cancer peptides with distinct characteristics expands as a result of the development of novel technologies and platforms by various pharmaceutical companies. This will provide diverse market opportunities for each and every therapeutic peptide product candidate. Furthermore, rise in the cancer prevalence and increasing research of the therapeutic use of cancer peptides is likely to be the key factors responsible for the growth of the market. Moreover, the increasing demand for effective and novel therapies can be further anticipated to bring more opportunities and growth in the market. Apart from this, awareness among healthcare professionals and patients about the significant adverse events associated with conventional cancer treatments will also lead to greater adoption towards peptide based therapeutics in cancer treatment.

Our report provides a comprehensive analysis about the current available anti-cancer peptide drugs and therapies while also providing information about their sales insight, patent information and their targeting cancer indication. Additionally, this report also includes the overall market perspective of peptides in different countries and provides a descriptive view on upcoming opportunities that might become available.

Content
Table of Contents

1. Introduction to Peptide Therapeutics
1.1 Overview of Peptide Therapeutics
1.2 Classification Of Anticancer Peptides
1.3 Significance of Peptides as Cancer Therapeutics

2. Global Cancer Peptide Therapeutics Market Insight
2.1 Current Market Scenario
2.2 Global Cancer Peptide Therapeutics Market Forecast

3. Global Peptide Cancer Therapeutics Market Trend By Region
3.1 Japan
3.2 South Korea
3.3 China
3.4 Australia
3.5 US
3.6 Europe

4. Marketed Cancer Peptides Drugs Insight – Availability, Cost, Dosage, Indication & Patent Insight
4.1 Firmagon (Degarelix)
4.2 Eligard (Leuprolide)
4.3 Lupron (Leuprolide Acetate)
4.4 Supprelin LA (Histrelin Acetate)
4.5 Gonax (Degarelix Acetate)
4.6 Trelstar (Triptorelin)
4.7 Decapeptyl SR (Treptorelin Acetate or Pamoate)
4.8 Velcade (Bortizomib)
4.9 Ninlaro (Ixazomib)
4.10 Kyprolis (Carfilzomib)
4.11 Istodax (Romidepsin)
4.12 Zoladex (Goserelin)
4.13 Cosmegen (Dactinomycin)
4.14 Somatuline Depot (Lanreotide)
4.15 Suprefact (Buserelin)
4.16 Sandostatin (Octreotide Acetate)
4.17 Bynfezia Pen (Octreotide)
4.18 Mepact (Mifamurtide)
4.19 Lutathera (Lutetium Lu 177 dotatate)
4.20 Netspot (Gallium Ga 68 dotatate)

5. Marketed Cancer Peptides Drugs Sales Insight (2019 -2023)
5.1 Lupron
5.2 Kyprolis
5.3 Zoladex
5.4 Lutathera
5.5 Sandostatin
5.6 Somatuline
5.7 Decapeptyl SR
5.8 Velcade
5.9 Ninlaro

6. Global Peptide Cancer Therapeutics Clinical Trials Overview
6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Patient Segment
6.5 By Phase
6.6 By Drug Formulation

7. Global Peptide Cancer Therapeutics Clinical Trials Insight By Company, Country, Indication & Peptide Segment
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III
7.8 Preregistration
7.9 Registered

8. Marketed Cancer Peptides Clinical Insight by Company, Country & Indication

9. Global Peptide Cancer Therapy Market Dynamics
9.1 Favorable Market Parameters
9.2 Commercialization Challenges

10. Targets for Therapeutic Peptides
10.1 Signal Transduction Pathways
10.2 Cell Cycle Regulation
10.3 Cell Death Pathways
10.4 Tumor Suppressor Protein
10.5 Transcription Factors

11. Peptide Drugs v/s Conventional Cancer Therapeutics
11.1 Peptide v/s Chemotherapy
11.2 Peptide v/s Monoclonal Antibody
11.3 Peptide v/s Gene Therapy
11.4 Peptide v/s Immunotherapy

12. Different Approaches of Peptides in Cancer Therapeutics
12.1 Hormonal Peptides
12.2 Peptide as Radionuclide Drug Carrier
12.3 Peptide Vaccines
12.4 Peptides as Cytotoxic Drug Carrier
12.5 Anticancer Peptides
12.6 Other Anticancer Drugs Closely Related to Peptides

13. Application of Peptides Therapeutics & Detection Methodology by Cancer

13.1 Colorectal Cancer
13.1.1 Peptides in Treatment of Colorectal Cancer
13.1.2 Proprietary Technologies

13.2 Lung Cancer
13.2.1 Peptides in Treatment of Lung Cancer
13.2.2 Proprietary Technologies

13.3 Pancreatic Cancer
13.3.1 Peptide in Treatment of Pancreatic Cancer
13.3.2 Proprietary Technologies

13.4 Gastric Cancer
13.4.1 Peptides in Treatment of Gastric Cancer
13.4.2 Proprietary Technologies

13.5 Breast Cancer
13.5.1 Peptides in Treatment of Breast Cancer
13.5.2 Proprietary Technologies

13.6 Prostate Cancer
13.6.1 Peptides in Treatment of Prostate Cancer
13.6.2 Proprietary Technologies

14. Neoantigen Vaccine: An Emerging Tumor Immunotherapy
14.1 Personalized Neoantigen Based Vaccine in Cancer
14.2 Ongoing Clinical Advancements

15. Venom Peptides: New Era for Cancer Peptide Therapy
15.1 Relevance of Venom Based Peptide Therapeutics
15.2 Recent Clinical Trials & Future Growth Avenues of Venom Peptides

16. Competitive Landscape
16.1 3B Pharmaceuticals
16.2 AsclepiX Therapeutics
16.3 Bicycle Therapeutics
16.4 Biohaven Labs
16.5 BrightPath Biotherapeutics
16.6 Bristol-Myers Squibb
16.7 Edinburgh Molecular Imaging
16.8 FogPharma
16.9 GE Healthcare
16.10 Gnubiotics Sciences
16.11 Harvard University
16.12 Heidelberg Pharma AG
16.13 IDP Pharma
16.14 Janux Therapeutics
16.15 Medikine
16.16 Modulation Therapeutics
16.17 Novartis
16.18 PeptiDream
16.19 Pharm-Sintez
16.20 Roche
16.21 Sanofi
16.22 Sapience Therapeutics
16.23 Second Genome
16.24 Viewpoint Molecular Targeting
16.25 Vigeo Therapeutics

List of Table
Table 1-1: Source or Chemical Nature of Early Peptides

Table 4-1: Velcade - Dosage Regimen for Patients with Previously Untreated Multiple Myeloma

Table 12-1: Peptides in Clinical Trials

Table 13-1: Peptides & Their Targets in Colorectal Cancer
Table 13-2: Colorectal Cancer – Peptide Based Therapies Currently Under Clinical Trials
Table 13-3: Lung Cancer - Peptide Based Therapies Currently Under Clinical Trials
Table 13-4: Antigens Utilized as Molecular Targets
Table 13-5: Pancreatic Cancer - Peptide Based Therapies Currently Under Clinical Trials
Table 13-6: Gastric Cancer – - Peptide Based Therapies Currently Under Clinical Trials
Table 13-7: Breast Cancer - Peptide Vaccines under Development
Table 13-8: Prostate Cancer – Examples of Therapeutic Peptides

Table 14-1: Global – Late Stage Neoantigen Vaccines

Table 15-1: Other Venom Peptides in Cancer Therapy